Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions

Prurigo NodularisItch

Interventions

DRUG

Tofacitinib 5 MG

5mg tofacitinib tablet twice daily

Trial Locations (1)

Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou

All Listed Sponsors

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT06201715 - Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis | Biotech Hunter | Biotech Hunter